ImmunityBio
IBRX
IBRX
58 hedge funds and large institutions have $12.7M invested in ImmunityBio in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
36% less call options, than puts
Call options by funds: $83K | Put options by funds: $130K
Holders
58
Holding in Top 10
–
Calls
$83K
Puts
$130K
Top Buyers
| 1 | +$245K | |
| 2 | +$198K | |
| 3 | +$108K | |
| 4 |
Bank of New York Mellon
New York
|
+$94.2K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$89.4K |
Top Sellers
| 1 | -$270K | |
| 2 | -$259K | |
| 3 | -$210K | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$177K |
| 5 |
Millennium Management
New York
|
-$129K |